Audio and slides for this presentation are available on YouTube: http://youtu.be/Q_wdfcJO3XE
Ann LaCasce, MD, MMSc, of Dana-Farber/Brigham and Women's Cancer Center Adult Lymphoma Program, talks about new clinical trials and treatments available for lymphoma patients. This presentation was originally given at the Lymphoma Research Foundation North American Forum on Sept. 28, 2013. http://www.dana-farber.org | http://www.lymphoma.org
This is NHL clinical update on 57th ASH Annual Meeting and Exposition (December 5-8, 2015).
It includes only clinical aspects include both chemotherapy and antibody therapy.
Overview of clinical trials for metastatic triple-negative breast cancer by Sara M. Tolaney, MD, MPH, Associate Director and Associate Director of Clinical Research at Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.
What's the latest in breast cancer treatment and research? Erica Mayer, MD, MPH, a medical oncologist in the Susan F. Smith Center for Women's Cancers, shares the latest breast cancer news.
This presentation was originally given on Oct. 16, 2015, at the annual Young Women with Breast Cancer Forum, hosted by the Program for Young Women with Breast Cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, in Boston, Mass.
Learn more: http://www.susanfsmith.org
Audio and slides for this presentation are available on YouTube: http://youtu.be/7iFnx9y_cCw
Arnie Freedman, MD, clinical director of the Dana-Farber/Brigham and Women's Cancer Center Adult Lymphoma Program, discusses several options for maintenance therapy of lymphoma, and the pros and cons of each. This presentation was originally given at the Lymphoma Research Foundation's 2013 North American Forum on Sept. 29, 2013. http://www.dana-farber.org | http://www.lymphoma.org
This is NHL clinical update on 57th ASH Annual Meeting and Exposition (December 5-8, 2015).
It includes only clinical aspects include both chemotherapy and antibody therapy.
Overview of clinical trials for metastatic triple-negative breast cancer by Sara M. Tolaney, MD, MPH, Associate Director and Associate Director of Clinical Research at Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.
What's the latest in breast cancer treatment and research? Erica Mayer, MD, MPH, a medical oncologist in the Susan F. Smith Center for Women's Cancers, shares the latest breast cancer news.
This presentation was originally given on Oct. 16, 2015, at the annual Young Women with Breast Cancer Forum, hosted by the Program for Young Women with Breast Cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, in Boston, Mass.
Learn more: http://www.susanfsmith.org
Audio and slides for this presentation are available on YouTube: http://youtu.be/7iFnx9y_cCw
Arnie Freedman, MD, clinical director of the Dana-Farber/Brigham and Women's Cancer Center Adult Lymphoma Program, discusses several options for maintenance therapy of lymphoma, and the pros and cons of each. This presentation was originally given at the Lymphoma Research Foundation's 2013 North American Forum on Sept. 29, 2013. http://www.dana-farber.org | http://www.lymphoma.org
Learn about the latest treatment options for advanced triple-negative breast cancer. Nancy Lin, MD, a breast oncologist in the Susan F. Smith Center for Women's Cancers at Dana-Farber, discusses new research.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held at Dana-Farber Cancer Institute in Boston, Mass. on Oct. 17, 2015.
More information is available at http://www.susanfsmith.org.
Despite remarkable progress in the treatment of HER2+ breast cancer, management of this patient population continues to remain a challenge, both in the adjuvant and metastatic settings. An enhanced understanding of the treatment options available for HER2+ breast cancer patients in different settings is imperative to improving patient survival and quality of life. This activity consisting of didactic presentations and case illustrations will address treatment choices for HER2+ patients after trastuzumab progression; proposed mechanisms of resistance; combination treatment approaches; the role of anthracyclines and HER2-targeted agents in this population; and novel targeted agents under investigation, including mTOR inhibitors, antiangiogenic inhibitors, and HER2-targeted therapies.
More information:
http://imeronline.com/867dsd
Review a downloadable slide deck by Kathy D. Miller, MD, covering the most clinically relevant new data reported from Future Directions in the Treatment of Patients With HER2+ Breast Cancer: What Community Oncologists Need to Know.
Target Audience
This activity is designed to meet the educational needs of oncologists and other healthcare professionals involved in cancer care.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of September 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
More information:
http://imeronline.com/867dsd
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Audio and slides for this presentation are available on YouTube: http://youtu.be/rAgnoymx0DQ
Dr. Ann LaCasce talks about the various treatments for lymphoma, including chemotherapy and radiation therapy methods, as well as the role of clinical trials. This presentation was first given at a lymphoma workshop presented by the Lymphoma Research Foundation (www.lymphoma.org).
Triple Negative Breast Cancer and Women of Color (Slide 2)bkling
In this webinar, Dr. Onyinye D. Balogun and Dr. Lisa Newman of Weill Cornell Medicine-New York Presbyterian Hospital Network discuss all aspects of triple negative breast cancer and its impact on women of color in recognition of Black History Month
Audio and slides for this presentation are available on YouTube: http://youtu.be/pkB_mfPtjrA
Andrea K. Ng, MD, of Dana-Farber/Brigham and Women's Cancer Center Department of Radiation Oncology, gives an overview of the different types of radiation therapy, the side effects, and how it is used in the treatment of lymphoma. This presentation was given at the 2013 Lymphoma Research Foundation North American Forum on Sept. 29, 2013. http://www.dana-farber.org | http://www.lymphoma.org
Myron Czuczman, M.D., Professor Chief, Lymphoma/Myeloma Service, Dept. of Medicine Head, Lymphoma Translational Research Laboratory Dept. of Immunology Roswell Park Cancer Center
Evolving Management of Follicular Lymphoma
Presented at New Frontiers in the Management of Solid and Liquid Tumors hosted by the John Theurer Cancer Center at Hackensack University Medical Center. jtcancercenter.org/CME
Learn about the latest treatment options for advanced triple-negative breast cancer. Nancy Lin, MD, a breast oncologist in the Susan F. Smith Center for Women's Cancers at Dana-Farber, discusses new research.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held at Dana-Farber Cancer Institute in Boston, Mass. on Oct. 17, 2015.
More information is available at http://www.susanfsmith.org.
Despite remarkable progress in the treatment of HER2+ breast cancer, management of this patient population continues to remain a challenge, both in the adjuvant and metastatic settings. An enhanced understanding of the treatment options available for HER2+ breast cancer patients in different settings is imperative to improving patient survival and quality of life. This activity consisting of didactic presentations and case illustrations will address treatment choices for HER2+ patients after trastuzumab progression; proposed mechanisms of resistance; combination treatment approaches; the role of anthracyclines and HER2-targeted agents in this population; and novel targeted agents under investigation, including mTOR inhibitors, antiangiogenic inhibitors, and HER2-targeted therapies.
More information:
http://imeronline.com/867dsd
Review a downloadable slide deck by Kathy D. Miller, MD, covering the most clinically relevant new data reported from Future Directions in the Treatment of Patients With HER2+ Breast Cancer: What Community Oncologists Need to Know.
Target Audience
This activity is designed to meet the educational needs of oncologists and other healthcare professionals involved in cancer care.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of September 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
More information:
http://imeronline.com/867dsd
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Audio and slides for this presentation are available on YouTube: http://youtu.be/rAgnoymx0DQ
Dr. Ann LaCasce talks about the various treatments for lymphoma, including chemotherapy and radiation therapy methods, as well as the role of clinical trials. This presentation was first given at a lymphoma workshop presented by the Lymphoma Research Foundation (www.lymphoma.org).
Triple Negative Breast Cancer and Women of Color (Slide 2)bkling
In this webinar, Dr. Onyinye D. Balogun and Dr. Lisa Newman of Weill Cornell Medicine-New York Presbyterian Hospital Network discuss all aspects of triple negative breast cancer and its impact on women of color in recognition of Black History Month
Audio and slides for this presentation are available on YouTube: http://youtu.be/pkB_mfPtjrA
Andrea K. Ng, MD, of Dana-Farber/Brigham and Women's Cancer Center Department of Radiation Oncology, gives an overview of the different types of radiation therapy, the side effects, and how it is used in the treatment of lymphoma. This presentation was given at the 2013 Lymphoma Research Foundation North American Forum on Sept. 29, 2013. http://www.dana-farber.org | http://www.lymphoma.org
Myron Czuczman, M.D., Professor Chief, Lymphoma/Myeloma Service, Dept. of Medicine Head, Lymphoma Translational Research Laboratory Dept. of Immunology Roswell Park Cancer Center
Evolving Management of Follicular Lymphoma
Presented at New Frontiers in the Management of Solid and Liquid Tumors hosted by the John Theurer Cancer Center at Hackensack University Medical Center. jtcancercenter.org/CME
Although lymphoma diagnoses are often categorized as either Hodgkin lymphoma or non-Hodgkin lymphoma, there are many subtypes of each disease, with more than 50 subtypes of non-Hodgkin lymphoma alone.
Final presentation for BIOL405, NSC, Spring 2014. Presented by Kevin Hugins and Duy-Khiem Chanh Pham. This presentation addressed the use of Chimeric Antigen Receptors for gene therapy for cancer. Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Understand the concept of Colorectal Cancer clinical trials and the differences across the phases. Presented by Dr. Sam J. Lubner MD, FACP University of Wisconsin Carbone Cancer Center
Join Fight CRC and Dr. Scott Kopetz to learn about the latest breaking colorectal cancer research from the American Society of Clinical Oncology 2019 Annual Conference.
Don't miss our upcoming webinars! Subscribe today!
Presented by: Dr. Poul Sorensen, MD, PhD, FRCPC; Dr. Muhammad Zulfiqar, MD; Ted Taylor, Patient Advocate
In this webinar, we will hear from Dr. Sorensen about his groundbreaking discovery and how it contributed to the development of tumour agnostic treatments. Dr. Zulfiqar, a medical oncologist at the BC Cancer Agency, will further discuss TRK fusion cancers and how he has been able to treat patients. Lastly, we will hear from Ted Taylor, a TRK fusion cancer patient diagnosed with glioblastoma (GBM) multiform being treated with Vitrakvi.
Watch the YouTube video: https://youtu.be/RAkItUeZ23Q
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Learn about the latest research and treatment for ER+ breast cancer. Erica Mayer, MD, MPH, medical oncologist with the Susan F. Smith Center for Women's Cancers, discusses new clinical trials and treatment options for this subset of breast cancer patient.
This presentation was originally given on Oct. 17, 2015, at the Metastatic Breast Cancer Forum, hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, in Boston, Mass.
Learn more: http://www.susanfsmith.org
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Krista Noonan is a medical oncologist specializing in thoracic and genitourinary malignancies at BC Cancer, Surrey Centre. Her research interests focus on thoracic and genitourinary malignancies and health services research. On Thursday, February 27, join Dr. Noonan as she: - Reviews the advancements in systemic therapy in lung cancer over the past decade - Highlights how the advancements in systemic therapy have dramatically improved quality of life and length of life.
View the video: https://youtu.be/3DaUwQ8ab44
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Roundtable Expert Discussions on CML Clinical Debates: A Collaborative Video Viewpoint Series With Medscape
This video viewpoint in its original and unaltered format is for educational purposes and is current as of May 31, 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at the user’s own risk, and all users should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Similar to Clinical Trials, Emerging New Drugs and Future Concepts in the Treatment of Lymphoma (20)
Commonly thought of as a childhood cancer, leukemia is actually much more common in adults. While symptoms of the disease are consistent among each, researchers are beginning to understand more about underlying biological factors that influence the different ways leukemia develops in children and adults. What are other differences and similarities?
An overview of Clinical Trials for Metastatic HER2-positive Breast Cancer by Dr. Ian Krop, MD, PhD, Chief and Clinical Research Director, Breast Oncology Center at Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute
Research increasingly shows that “energy balance” is important in breast cancer. Learn why exercise, weight, and diet are important for breast cancer patients.
Prostate cancer is a disease in which cancer forms in the tissues of the prostate, a male gland just below the bladder and in front of the rectum. Prostate cancer is rare in men younger than 50 years of age, and the chance of developing prostate cancer increases as men get older. In the United States, a man has a one in five chance of being diagnosed with prostate cancer in his lifetime.
There are many different pediatric brain tumor types and classifications based upon the tumor’s cell structure, composition, rate of growth, location, and other characteristics. A child’s tumor may have the same microscopic appearance to an adult tumor, but the mutations that cause its growth are completely different.
Soft tissue sarcoma refers to cancer that begins in the muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body. View the slideshow to learn more about signs and symptoms of this cancer, as well as risk factors.
Cancer-related fatigue is one of the most common problems patients face. Patients often report feeling wiped out during cancer treatments like chemotherapy and radiation, and for many, feeling tired or worn out continues into life after cancer treatment.
Here are 10 tips for alleviating treatment-related fatigue, through methods such as energy preservation and exercise – the latter of which is now known to be an effective strategy for combating this prevalent side effect.
There are more than 120 different types of brain tumors that may occur in adults. Learn about the five most common types.
For more on brain tumors, visit www.dana-farber.org/braintumor
Multiple myeloma is a type of cancer that begins in plasma cells, white blood cells that produce antibodies. It is also called Kahler's disease, myelomatosis or plasma cell myeloma.
Integrative therapies range from individual treatments, such as acupuncture, massage, and Reiki, to group programs for movement, meditation, and creative arts, as well as exercise and nutritional consultations.
Research conducted by Dana-Farber investigators and others has shown that, when used in conjunction with traditional cancer care, integrative therapies can help ease cancer-related symptoms and improve your quality of life.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Clinical Trials, Emerging New Drugs and Future Concepts in the Treatment of Lymphoma
1. Clinical Trials, Emerging New
Drugs and Future Concepts in
the Treatment of Lymphoma
Ann S. LaCasce, MD, MMSc
Medical Oncologist, Dana-Farber/Brigham and Women’s Cancer
Center Adult Lymphoma Program
Assistant Professor, Harvard Medical School
Director, Dana-Farber/Partners CancerCare Hematology-Medical
Oncology Fellowship Program
2. What is a clinical trial?
• Test the safety and how well a new drug
works in a particular disease
• Test the safety and how well an established
drug works in a new disease
• Compare a new medication to standard
treatment
• Goal for FDA approval of a drug for a
particular use
3. History of clinical trials
Established rules for clinical trial –
• drug must be used on simple, not
composite disease
• quality of drug must correspond
with strength of disease
• must be tested on two contrary
diseases
• time action must be observed
• must be performed on humans
Avicenna, Persian physician and philosopher (1025)
6. NIH – types of trials
Prevention
Prevention
Screening
Screening
Diagnostic
Diagnostic
Treatment
Treatment
Quality
Quality
of Life
of Life
Compassionate
Compassionate
use
use
8. New drug clinical trials
Phase 1
Phase 1
Safety
Safety
20-100 pts
1st in humans
dose, schedule
9. New drug clinical trials
Phase 1
Phase 1
Safety
Safety
20-100 pts
1st in humans
dose, schedule
Phase 2
Phase 2
Efficacy
Efficacy
100-500 pts
How well does
it work?
10. New drug clinical trials
Phase 1
Phase 1
Safety
Safety
20-100 pts
1st in humans
dose, schedule
Phase 2
Phase 2
Efficacy
Efficacy
100-500 pts
How well does
it work?
Phase 3
Phase 3
Confirm
Confirm
>1,000 pts
Compare with
standard of care &
study safety
11. New drug clinical trials
Phase 1
Phase 1
Safety
Safety
20-100 pts
1st in humans
dose, schedule
Phase 2
Phase 2
Efficacy
Efficacy
100-500 pts
How well does
it work?
Phase 3
Phase 3
Confirm
Confirm
>1,000 pts
Compare with
standard of care &
study safety
FDA review
FDA review
Phase 4
Phase 4
Safety in typical
patients
12. Phase I
• In non-cancer studies performed in healthy
volunteers
• In drugs directed against cancer, typically given to
patients with different types of cancer
• Establish safe dose and schedule
• Evaluate side effects
• Give preliminary information regarding if the drug
works
13. Phase I clinical trial of anti-CD20 monoclonal
antibody in recurrent B-cell lymphoma
3 pts
3 pts
10 mg/m2
10 mg/m2
3 pts
3 pts
50 mg/m2
50 mg/m2
3 pts
3 pts
100 mg/m2
100 mg/m2
3 pts
3 pts
250 mg/m2
250 mg/m2
3 pts
3 pts
500 mg/m2
500 mg/m2
Side effects: fever (5); nausea (2), chills(2), low
blood pressure (2), wheezing (1), low platelets (1)
Lymphoma responded in more than half of patients
14. Phase II
The drug or treatment is given to a larger group of people
to see if it is effective and to further evaluate its safety
15. Rituximab therapy for relapsed indolent
lymphoma
• 166 patients
• IDEC-C2B8 375 mg/m2 intravenously weekly for
four doses
• Fever and chills were the most common events
• Low incidence of serious side effects
• Approximately half of patients responded
• FDA approves the drug
16. Phase III clinical trial
In cancer studies, typically no
placebo except in certain
circumstances
17. CHOP plus rituximab versus CHOP in older patients
with diffuse large-B-cell lymphoma
399 pts
Age 60-80
18. CHOP plus rituximab versus CHOP in older patients
with diffuse large-B-cell lymphoma
RCHOP
399 pts
Age 60-80
19. CHOP plus rituximab versus CHOP in older patients
with diffuse large-B-cell lymphoma
RCHOP
399 pts
Age 60-80
CHOP
RCHOP superior and becomes standard treatment
20. Phase IV
After drug approved by FDA
Collect additional information on side effects
Identify any rare or long term toxicity
21. Oversight
• Studies may be conducted by pharmaceutical
companies, single or group of investigators
(including cooperative groups)
• Careful oversight to ensure ethical and safe conduct
• Institutional Review Board (IRB)
– Evaluate protocol
– Review consent form
– Oversee ongoing conduct of trial
25. FDA definitions
Fast Track:
Fast Track:
Frequent meetings with
Frequent meetings with
FDA re drug
FDA re drug
development plan
development plan
Eligible for accelerated
Eligible for accelerated
approval and priority
approval and priority
review, if relevant
review, if relevant
criteria are met
criteria are met
Rolling review
Rolling review
26. FDA definitions
Fast Track:
Fast Track:
Breakthrough Therapy:
Breakthrough Therapy:
Frequent meetings with
Frequent meetings with
FDA re drug
FDA re drug
development plan
development plan
All Fast Track features
All Fast Track features
Eligible for accelerated
Eligible for accelerated
approval and priority
approval and priority
review, if relevant
review, if relevant
criteria are met
criteria are met
Rolling review
Rolling review
Intensive guidance on
Intensive guidance on
drug development
drug development
program, beginning as
program, beginning as
early as Phase 1
early as Phase 1
Organizational
Organizational
commitment involving
commitment involving
senior managers
senior managers
29. SGN-30
CD30
Anti-CD30 antibody
• Phase 2 study in patients with HL or
CD30+ anaplastic large cell lymphoma
• Several patients with T-cell lymphoma
experienced disease improvement
but activity disappointing
• Favorable side effect profile
CD 30 positive lymphoma cell
30. Brentuximab vedotin
Antibody drug conjugate (ADC)
Chemotherapy drug (MMAE)
Antibody
CD-30
ADC binds to CD30
ADC-CD30 complex
taken into cell
MMAE is released
MMAE disrupts
microtubule network
G2/M cell
cycle arrest
Cell dies
31. Brentuximab vedotin FDA approval
Hodgkin lymphoma
Hodgkin lymphoma
Phase 2 study
Phase 2 study
Relapsed disease
Relapsed disease
Anaplastic large cell
Anaplastic large cell
lymphoma
lymphoma
Phase 2 study
Phase 2 study
Relapsed disease
Relapsed disease
Extremely active drug in both diseases
Manageable side effect profile with peripheral
neuropathy as predominant issue
32. Brentuximab vedotin FDA approval
Hodgkin lymphoma
Hodgkin lymphoma
Phase 2 study
Phase 2 study
Relapsed disease
Relapsed disease
Anaplastic large cell
Anaplastic large cell
lymphoma
lymphoma
Phase 2 study
Phase 2 study
Relapsed disease
Relapsed disease
Extremely active drug in both diseases
Manageable side effect profile with peripheral
neuropathy as predominant issue
39. Brentuximab development NHL
Phase 2
Phase 2
relapsed CD30+
relapsed CD30+
NHL
NHL
BV+CHP
BV+CHP
Phase 3
Phase 3
CD30+
CD30+
NHL
NHL
CHOP
CHOP
40. Learning from the past
• Thalidomide with a checkered past
• Introduced in the late 50’s as
a sedative thought to be safe
for pregnant women with morning
sickness
• Tragic toxicity of limb deformities
• 1990’s found to have activity in
leprosy and HIV
• Later found to be active in multiple
myeloma and approved as initial
therapy by FDA in 2006
• Prominent side effects of neuropathy
and fatigue
46. Evolution of front-line therapy in follicular
lymphoma
CHOP or CVP conventional chemotherapy
47. Evolution of front-line therapy in follicular
lymphoma
CHOP or CVP conventional chemotherapy
CHOP or CVP plus rituximab
48. Evolution of front-line therapy in follicular
lymphoma
CHOP or CVP conventional chemotherapy
CHOP or CVP plus rituximab
Bendamustine plus rituximab
49. Evolution of front-line therapy in follicular
lymphoma
CHOP or CVP conventional chemotherapy
CHOP or CVP plus rituximab
Bendamustine plus rituximab
Lenaliomide plus rituximab
50. Evolution of front-line therapy in follicular
lymphoma
CHOP or CVP conventional chemotherapy
CHOP or CVP plus rituximab
Bendamustine plus rituximab
Lenaliomide plus rituximab
Lenaliomide plus rituximab ? + additional novel agent
56. Idelalisib
Submitted to
Submitted to
the FDA
the FDA
in rituximab
in rituximab
refractory
refractory
iNHL
iNHL
On-going
On-going
clinical trials
clinical trials
oral drug
favorable side effect profile
CLL
CLL
MCL
MCL
iNHL
iNHL
57. Personalized medicine in lymphoma
Targeting ABC
Targeting ABC
DLBCL
DLBCL
Ibrutinib
Ibrutinib
Tissue biopsy to
Tissue biopsy to
determine DLBCL
determine DLBCL
subtype
subtype
lenalidomide
lenalidomide